BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+5.04%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.97B
AUM Growth
-$106M
(-1.5%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$25.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$24.6M |
| 3 |
Exact Sciences
EXAS
|
$12.1M |
| 4 |
Tandem Diabetes Care
TNDM
|
$12M |
| 5 |
Charles River Laboratories
CRL
|
$6.28M |
Top Sells
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$20.3M |
| 5 |
Axsome Therapeutics
AXSM
|
$14.3M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Energy | 0.02% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTEM
101
DELISTED
Molecular Templates, Inc.
MTEM
| $8.46M | 0.12% |
751,867
| – | – |
|
102
Black Diamond Therapeutics
BDTX
$162M
| $7.97M | 0.11% |
4,717,113
| – | – |
|
103
Biogen
BIIB
$20.3B
| $7.67M | 0.11% |
28,735
+6,885
| +32% | +$1.84M |
|
104
10x Genomics
TXG
$1.64B
| $7.24M | 0.1% |
254,134
-5,237
| -2% | -$149K |
|
105
American Well
AMWL
$108M
| $6.35M | 0.09% |
88,485
| – | – |
|
106
Teleflex
TFX
$5.64B
| $6.34M | 0.09% |
31,480
-64,504
| -67% | -$13M |
|
107
Gilead Sciences
GILD
$141B
| $6.04M | 0.09% |
97,854
+22,428
| +30% | +$1.38M |
|
|
SGEN
108
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.87M | 0.08% |
42,926
-6,450
| -13% | -$883K |
|
109
Doximity
DOCS
$12.6B
| $5.85M | 0.08% |
193,439
+57,117
| +42% | +$1.73M |
|
110
Johnson & Johnson
JNJ
$429B
| $5.01M | 0.07% |
30,671
+1,757
| +6% | +$287K |
|
111
BioMarin Pharmaceuticals
BMRN
$11B
| $4.54M | 0.07% |
53,493
-20,260
| -27% | -$1.72M |
|
112
Supernus Pharmaceuticals
SUPN
$2.52B
| $4.04M | 0.06% |
119,278
+36,878
| +45% | +$1.25M |
|
113
Cytokinetics
CYTK
$6.07B
| $3.45M | 0.05% |
71,200
+4,800
| +7% | +$233K |
|
114
Guardant Health
GH
$7.36B
| $3.34M | 0.05% |
62,083
-8,497
| -12% | -$457K |
|
115
Eli Lilly
LLY
$663B
| $3.07M | 0.04% |
9,490
+8,521
| +879% | +$2.76M |
|
116
Pulmonx
LUNG
$66M
| $2.89M | 0.04% |
173,336
| – | – |
|
|
OLK
117
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $2.8M | 0.04% |
230,522
-4,751
| -2% | -$57.7K |
|
118
Q32 Bio
QTTB
$20.5M
| $2.61M | 0.04% |
90,140
| – | – |
|
119
AstraZeneca
AZN
$254B
| $2.46M | 0.04% |
44,400
-42,600
| -49% | -$2.36M |
|
|
BCYC
120
Bicycle Therapeutics
BCYC
$475M
| $2.28M | 0.03% |
98,100
+13,700
| +16% | +$319K |
|
121
AbbVie
ABBV
$377B
| $2.28M | 0.03% |
16,997
+16,189
| +2,004% | +$2.17M |
|
122
Arcus Biosciences
RCUS
$1.22B
| $2.18M | 0.03% |
83,500
-6,600
| -7% | -$173K |
|
123
Relmada Therapeutics
RLMD
$47.5M
| $1.97M | 0.03% |
53,187
+18,187
| +52% | +$673K |
|
124
Sight Sciences
SGHT
$196M
| $1.87M | 0.03% |
294,606
| – | – |
|
125
Intellia Therapeutics
NTLA
$1.22B
| $1.71M | 0.02% |
30,478
+14,684
| +93% | +$822K |
|